Peter Barton Hutt

Peter Barton Hutt has served as a member of the Board of Directors since December 2006. Mr. Hutt has practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 (except for the period from 1971 to 1975) and currently serves as senior counsel. From 1971 to 1975, he was Chief Counsel for the Food and Drug Administration. Mr. Hutt also serves on the board of directors of Immunomedics, Inc. and Q Therapeutics, Inc., as well as numerous private companies. During the last five years, Mr. Hutt previously served on the board of directors of BIND Therapeutics, Inc., DBV Technologies SA, Flex Pharma, Inc., Moderna, Inc., Rubius Therapeutics, Inc., Seres Therapeutics, Inc., and XOMA Corporation Mr. Hutt received a B.A. from Yale University, an LL.B. from Harvard Law School and an LL.M. from New York University School of Law. They believe Mr. Hutt’s extensive knowledge of regulatory and legal issues related to drug development and his service on numerous boards of directors allow him to be a key contributor to the Board.